Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...

First announced early this year, KIOXIA's AiSAQ open-source software technology increases vector scalability by storing all RAG database elements on SSDs. It provides tuning options to prioritize ...

The science of gene therapy is enjoying a renaissance after ups and downs over the past 25 years. The heart of this field still largely relies on viral vector gene transfer systems that have evolved ...

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...

With KIOXIA AiSAQ (TM) technology now integrated into Milvus, Kioxia and the open-source community are enabling a new class of scalable, cost-efficient vector search solutions designed to meet the ...

Introgen Therapeutic’s (Austin, TX) p53-based INGN 225 cancer vaccine yielded promising safety and efficacy results in a Phase II trial in advanced small cell lung cancer. The personalized therapeutic ...

From 6-9th January, Vector will be showcasing practical solutions for developing and operating Software-Defined Vehicles ...

FOXO Technologies Inc. announced a non-binding agreement to acquire Vector Biosource Inc., a provider of biospecimen sourcing in the biotech and pharmaceutical sectors, with expected revenue of ...

COLLEGE PARK, Md., September 17, 2025--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the leader in the quantum computing and networking industries, today announced it has entered into a definitive agreement to ...